New antibody shows promise for rare blood cancers

NCT ID NCT03902184

Completed Disease control Sponsor: Innate Pharma Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a drug called lacutamab (IPH4102) in 170 people with advanced T-cell lymphoma, including Sezary syndrome and mycosis fungoides. The drug is an antibody that targets a protein on cancer cells. It was given alone or with chemotherapy to see if it could shrink tumors and improve quality of life. The study is now complete, and results will show how safe and effective the treatment is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lacutamab (IPH4102), a targeted antibody
What this could lead to: If successful, this could provide a new treatment option for people with advanced T-cell lymphoma who have not responded to other therapies.
What could go wrong: This is a phase 2 trial, so results are still early. The drug may not work for all patients, and side effects are possible. Further studies are needed before it becomes widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides primary cutaneous T-cell non-Hodgkin lymphoma Sezary syndrome T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA, T-CELL LYMPHOMA, T-CELL, CUTANEOUS MYCOSIS FUNGOIDES/SEZARY SYNDROME

Contacts and locations

Locations

ASST degli Spedali Civili di Brescia

Brescia, 25123, Italy
CET Centrum Medyczne Pratia Poznan ul. Poznanska 14

Skorzewo, 60-185, Poland
CHRU de Lille - Hopital Claude Huriez

Lille, 59037, France
CHRU de Montpellier - Hopital Saint Eloi

Montpellier, 34095, France
CHRU de Tours, Hôpital Trousseau

Chambray-lès-Tours, 37170, France
CHU Henri Mondor

Créteil, 94010, France
CHU de Bordeaux Saint André

Bordeaux, 33075, France
Centre Hospitalier Lyon-Sud

Lyon, 69310, France
Centre Hospitalier Universitaire (CHU) de Liege

Liège, 4000, Belgium
Charite - Universitaetsmedizin Berlin

Berlin, 10115, Germany
Columbia University Department of Dermatology

New York, New York, 10032, United States
Consorci Hospital General Universitari de Valencia Servicio de Dermatología

Valencia, 46014, Spain
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, 03756, United States
Hospital Clinic Barcelona

Barcelona, 08036, Spain
Hospital Clinico Universitario de Salamanca

Salamanca, 37007, Spain
Hospital Universitari i Politecnic La Fe

Valencia, 46026, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital del Mar

Barcelona, 08003, Spain
Hôpital Charles Nicolle-CHU de Rouen Clinique Dermatologie

Rouen, 76031, France
Hôpital Saint-Louis

Paris, 75010, France
IUCT Oncopôle

Toulouse, 31100, France
Inova Health Care Services

Fairfax, Virginia, 22031, United States
Institut Jules Bordet

Brussels, 1070, Belgium
Institut Paoli-Calmettes

Marseille, 13009, France
Institute of Hematology "Seràgnoli", Univeristy of Bologna

Bologna, 40138, Italy
Irvine Medical Center

Orange, California, 92868, United States
Istituto Dermopatico dell'Immacolata (IDI-IRCCS)

Roma, 00167, Italy
Johannes Wesling Klinikum Minden

Minden, 32429, Germany
MD Anderson Cancer Center

Houston, Texas, 77030-4009, United States
Medizinische Universitaet Wien

Vienna, 1090, Austria
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Nowotworow Ukladu Chlonnego

Warsaw, 02-781, Poland
Northwestern University The Feinberg School of Medicine

Chicago, Illinois, 60611, United States
Ruhr-University Bochum

Bochum, 44791, Germany
Stanford University

Stanford, California, 94305, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
UZ Leuven - campus Gasthuisberg

Leuven, 3000, Belgium
Universal Dermatology, PLLC68

Fairport, New York, 14450, United States
Universita di Torino, Ospedale le Molinette

Turin, 10126, Italy
Universitaetsklinikum Halle (Saale)

Halle, 06120, Germany
Universitaetsklinikum Muenster

Münster, 48149, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel

Kiel, 24105, Germany
Universitaetsmedizin Mannheim GmbH

Mannheim, 68167, Germany
University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
University of California, Los Angeles (UCLA) - Medical Center

Los Angeles, California, 90095, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Pittsburgh School of Medicine

Pittsburgh, Pennsylvania, 15208, United States
University of South Florida

Tampa, Florida, 33612, United States
Universitätsklinik für Dermatologie Medizinische Universität Graz

Graz, A-8036, Austria
Universitätsklinikum Frankfurt

Frankfurt, 60590, Germany
Uniwersyteckie Centrum Kliniczne, Klinika Dermatologii, Wenerologii i Alergologii ul. Smoluchowskiego 17

Gdansk, 80-214, Poland
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.